CRVONasdaqPharmaceutical PreparationsFiscal year ends December 31
CervoMed Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026
$2.31+0.07 (+3.12%)
Close on Oct 19, 2026
- Market cap
- $23.66M
- P/E (TTM)
- –
- Dividend yield
- –
CervoMed Inc. revenue by segment
By business segment
| Revenue | TTM Q1 14 | TTM Q4 13 | TTM Q3 13 | TTM Q2 13 | TTM Q1 13 | TTM Q4 12 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|
| ProElite | – | $72 | $72 | $216 | $287 | $375 | – | – |
| Total | – | $72 | $72 | $216 | $287 | $375 | – | – |
| Operating income | TTM Q1 14 | TTM Q4 13 | TTM Q3 13 | TTM Q2 13 | TTM Q1 13 | TTM Q4 12 | YoY |
|---|---|---|---|---|---|---|---|
| Other [Member] | -$468.59K | -$587 | -$29 | -$29 | -$9.02K | -$32 | +5093.8% |
| Total | -$469.60K | -$604 | $43 | $184 | -$8.82K | $105 | +5226.7% |
| ProElite | – | $70 | $72 | $213 | $278 | $137 | – |
By product or service
By region
From the segment and revenue-disaggregation notes of CervoMed's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.